rdo n S m it h a n d J. O 'H . T o b in D avid G w y n n e E v ans was b o rn in A th e rto n , n e a r M a n c h e ste r, on 6 S e p te m b e r 1909 of W elsh p are n ts; his fath e r, a sch o o lm aster, was from P e m b ro k e sh ire an d his m o th e r fro m B angor, N o rth W ales. H e w as the th ird of fo u r c h ild re n in a d istin g u ish e d fam ily. H is o ld er b ro th e r, M e re d ith G w y n n e , becam e P ro fe sso r of P hysical C h e m istry in L eed s an d late r in M a n c h e ste r an d was a F ellow o f th e R oyal Society. H is sister, L y n e tte G w y n n e , took a degree in m o d e rn languages at M a n c h e ste r U n iv e rsity and ta u g h t in g irls ' h igh schools. H is y o u n g e r b ro th e r, A lw yn G w y n n e , afte r h o ld in g a lec tu re sh ip in M a n c h e ste r U n iv e rsity was a p p o in te d to th e C h a ir of P hysical C h e m istry in C ard iff U n iv e rsity . D a v id left L eig h G ra m m a r School in 1928 at th e age of 18 years and w o rk ed for tw o years in a ju n io r capacity fo r the B ritish C o tto n G ro w e rs ' A ssociation at th e M a n c h e ste r C o tto n E xchange. H ow ever, w hen A lw yn w en t u p to M a n c h e ste r U n iv e rsity in 1931, D av id d ecid ed to go w ith him and b o th g ra d u a te d B .Sc. in physics and c h e m istry th re e years later and M .S c . after a fu rth e r year. A t th is tim e P ro fesso r M a itla n d in the D e p a rtm e n t of B acteriology w a n te d a ch em ist to help in th e p u b lic health lab o ra to ry w h ich was ru n by his d e p a rtm e n t. P ro fesso r L a p w o rth rec o m m e n d e d D avid for the p ost and th u s D avid e n te red the field of bacterio lo g y and im m u n o lo g y , to w hich he w as to c o n trib u te so m uch. H e was a p p o in te d D e m o n s tra to r and soon afterw ard s A ssistan t L e c tu re r in th e U n iv e rsity D e p a rtm e n t. D u rin g these early years he w orked w ith P ro fesso r M a itla n d on the toxins of Haemophilus pertussis (now Bordetella pertussis) and related o rganism s, w ork th a t p ro v id ed a so u n d basis for his su b se q u e n t in te rest in w h o o p in g cough im m u n iz a tio n and later for his ab id in g in te rest in v accination against o th e r diseases and in the sta n d a rd iz a tio n o f vaccines and antisera.
of B iological S ta n d a rd s u n d e r the d ire c tio n of Percival H a rtle y at the N atio n al In s titu te for M ed ical R esearch in H a m p ste a d , L o n d o n . H e c o n tin u e d to w ork on p e rtu ssis b u t, d u rin g th e w ar years, he an d H a rtle y w ere p a rtic u la rly c o n c ern e d w ith th e stu d y o f infectio n s w ith th e s p o re b ea rin g an aero b es resp o n sib le for gas g an g ren e and w ith th e p ro d u c tio n of s ta n d a rd a n tito x in s against th e ir to xins.
In 1947 E vans re tu rn e d to M a n c h e ste r to becom e R e a d e r in th e D e p a rtm e n t of B acteriology. H is heavy tea c h in g c o m m itm e n t in clu d e d m u ch o f th e teach in g of th e course for th e D ip lo m a in B acteriology w hich a ttra c te d stu d e n ts fro m all over th e w orld. O f th is p e rio d one o f his fo rm e r stu d e n ts, D r A n n e C a u n t has w ritte n :
' " D . G ." was th e in sp ira tio n and d riv in g force b e h in d th e course a n d his lectu res w ere a m odel for any U n iv e rsity teach er. H e knew w h at p o in ts he w an ted to p u t across, he d id so lucidly and often am usingly, b u t left en o u g h u n e x p lo re d areas to entice the s tu d e n t to th e lib ra ry to follow up th e su bject. H e also, in th e k in d est w ay, ta u g h t us how to w rite and d eliv er pap ers. M a n y o f the s tu d e n ts did n o t have E n g lish as a first language b u t even those w ho d id still had m u ch to learn. E ach in tu rn h ad to p re se n t a review to th e class and a w eek or so b e fo re h a n d w ould discuss th e p la n n e d p a p e r w ith D .G . H e did n o t d erid e or b e little th e d ra ft b u t fre q u e n tly th e resu lt of the discu ssio n w as th a t th e s tu d e n t w ould decide the w hole th in g n eed ed to be re w ritte n and w ould p ro ceed to do so u n d e r D .G .'s g u idance.
In this w ay he ta u g h t one how to w rite a p ap er, how to give it (never read directly fro m a script!) and how to stan d up to critical d iscu ssio n . M an y o f his p ast s tu d e n ts m u st now rate th is as one of the m o st valuable disciplines of th e course and his influence on th e teach in g of m icrobiology and on the sta n d a rd of c o m m u n ic a tio n is sp read w o rld -w id e .' H e was aw ard ed the D .S c. of M a n c h e ste r U n iv e rsity in 1948. D u rin g this second M a n c h e ste r p erio d , w ork on Clostridium welchii w as c o n tin u e d b u t his in te rests b ro ad e n e d to in clu d e enzym e and toxin p r o d u c tio n by sp o re -b e a rin g aerobes. A t this tim e, a w h o o p in g cough im m u n iz a tio n co m m ittee h ad been set up by the M edical R esearch C ouncil (M .R .C .), w ith S. P. B edson as C h a irm a n and E vans as S ecretary. E vans was p a rticu la rly co n cern ed in finding a lab o rato ry test to d e te rm in e the im m u n iz in g p o ten cy of different w ho o p in g cough vaccines for co m p ariso n w ith th e resu lts o f field trials b ein g m ade w ith the sam e vaccines. T h e first field trials w ere m ade in five areas of E n g lan d and W ales b etw een 1948 and 1951 and a second series of trials co n tin u e d until 1954. T h e se trials show ed the value of vaccination of c h ild ren against w h o o p in g cough and enabled the co m m ittee to establish a B ritish sta n d a rd p ertu ssis vaccine. In the course of lab o rato ry e x p erim en ts on vaccination of m ice, E vans and P erk in s fo u n d th a t w ith in a few h o u rs of in tra p erito n e a l injection of vaccine, m ice w ere resistan t to in tra ce reb ra l in o c u la tio n of Bordetella pertussis a n d th a t th is effect was specific b u t in d e p e n d e n t of an tib o d y : th e so called in te rfe re n c e im m u n ity .
In 1955 E v an s r e tu rn e d to H a m p ste a d as H e a d o f th e B iological S ta n d a rd s C o n tro l L a b o ra to ry a n d th re e years later was a p p o in te d D ire c to r o f th e D e p a rtm e n t o f B iological S ta n d a rd s at th e N a tio n a l I n s titu te fo r M ed ical R esearch in M ill H ill, w hile c o n tin u in g to head th e C o n tro l L a b o ra to ry . D u rin g th is p e rio d th e tw o final re p o rts on w h o o p ing c o u g h v a ccin atio n w ere p u b lish e d . It h ad been show n th a t th e p ro te c tiv e p o w e r o f vaccines ag ain st w h o o p in g co u g h in c h ild re n was p a ra lle led by th e ir p ro te c tiv e p o w er in m ice against in tra c e re b ra l in je c tio n of Bordetella pertussis. A sta n d a rd p e rtu ssis vaccine th a t gave good re su lts in c h ild re n was e sta b lish e d , against w h ich fresh vaccines co u ld be teste d in th e lab o ra to ry by th e m o u se -p ro te c tio n test. A b o u t th is tim e in ac tiv a ted p o lio m y elitis vaccine o f Salk ty p e was b e in g p re p a re d for g eneral im m u n iz a tio n , and to E v a n s 's d e p a rtm e n t fell the task of testin g these vaccines for safety a n d efficacy in p ro te c tin g against the disease. T h e safety te stin g in m o nkeys was so rigidly c o n tro lle d th a t no clinical p o lio m y elitis re su lte d fro m th e use of th e in activ ated vaccine. T h is vaccine w as su p e rse d e d after a few years by the a tte n u a te d live vaccines of S ab in ty p e, p a rtly because of th e ir ease of ad m in istra tio n and also because th e a tte n u a te d oral vaccine was th o u g h t to p ro d u ce in testin al im m u n ity so th a t th e c a rrie r rate in th o se v accin ated w ould be red u ced . T h e careful w ork in E v a n s 's d e p a rtm e n t e n su re d th a t b o th types of p oliom yelitis vaccine, w h ich have led to th e p ractical d isap p earan ce o f the disease from B ritain , w ere in tro d u c e d w ith o u t m ish ap .
A n o th e r aspect of E v a n s's w ork at the C o n tro l L a b o ra to ry was the e x a m in atio n of p rem ises for su ita b ility for vaccine p ro d u c tio n . T h e se visits w ere alw ays c o n d u c te d in a frien d ly and inform al m a n n e r w ith as m u ch benefit to th e visito rs as to th e m a n u fa c tu re rs them selves. T h e q u a in te st visit he m ade was to a sm allpox vaccine p ro d u c tio n lab o rato ry on the so u th bank of th e T h a m e s w here th e m eth o d s of m an u fa ctu re had n o t b een ch an g ed dow n the decades. C alves w ere b o u g h t from th e m ark e t, kep t for a sh o rt tim e to see th a t th ey w ere fit before b eing used for vaccine p ro d u c tio n , th e h a rv e sted m aterial b ein g processed by the original e q u ip m e n t used w hen the lab o rato ry was set up in the 19th c e n tu ry . V accine m ade by th is lab o rato ry was m ainly sent to m erc h an t ships or ex p o rte d and the lab o rato ry h ad received no com plaints. U n fo rtu n a te ly E vans and his colleagues had to reco m m en d closure as the sta n d a rd of p ro d u c tio n co n tro l was no t co n sid ered ad eq u ate for the second h alf of th e 20th cen tu ry ; and so a fascinating piece of m edical in d u stria l h isto ry d isap p eared .
In 1961 E vans was a p p o in te d to th e C h a ir of B acteriology and Im m u n o lo g y at the L o n d o n School of H ygiene and T ro p ic a l M edicine, a post th a t again involved teach in g of stu d e n ts taking the p o stg rad u ate D ip lo m a in B acteriology. B ut his teach in g load did n o t seriously interfere w ith his co n tin u in g p a rticip a tio n in trials of various vaccines. H e succeeded W ilson S m ith as C h a irm a n of th e M easles V accine C o m m itte e of th e M .R .C . and was C h a irm a n of in te rn a tio n a l sym posia on p e rtu ssis (90)* and on B acillus C a lm e tte -G u e rin (B .C .G .) vaccines (91).
In 1971 his help was so u g h t by th e J o in t R acing B oard to head an in q u iry into vaccin atio n against e q u in e influenza th a t had o c c u rre d in epizootic fo rm in th re e of th e p rev io u s ten years. In 1972 he jo in e d the V e te rin ary A dviso ry C o m m itte e of th e H o rse R ace B ettin g L evy B oard and a year later succeeded S ir Jo h n R itchie as C h a irm a n .
In 1967 he was m ade C h a irm a n of a Jo in t M .R .C ./D e p a rtm e n t of H ealth and Social S e c u rity (D .H .S .S .) W o rk in g P a rty to co n sid e r how the s ta n d a rd iz a tio n and c o n tro l of biological su b stan ces sh o u ld be o rg an ized w ith in th e N atio n al In s titu te for M edical R esearch. F o llow ing th e W o rk in g P a r ty 's re p o rt a Jo in t C o m m itte e on S ta n d a rd iz a tio n was fo rm ed in 1968, w ith E vans as C h a irm a n , to m anage th e w ork on b e h a lf of the M .R .C . M ean w h ile in 1971, he had resigned his C h a ir at th e L o n d o n School to becom e D ire c to r of th e L iste r In stitu te w h ere he stru g g led in vain against financial ad v ersity to save its C helsea lab o rato ry .
U n d e r th e Jo in t C o m m itte e on S ta n d a rd iz a tio n the w ork on s ta n d a rd iz atio n and co n tro l was c o n so lid ated at th e H a m p ste a d L a b o rato rie s and in 1972 E vans was a p p o in te d D ire c to r of the new o rg an izatio n , w hich was th en m ade in d e p e n d e n t from th e N a tio n a l In s titu te for M edical R esearch and n am ed th e N a tio n a l In s titu te for Biological S ta n d a rd s and C o n tro l. H e reo rg an ized th e ex isting tw o M .R .C . divisions into nine scientific d e p a rtm e n ts and in itia ted th e p lan n in g of the new lab o rato ries for the In s titu te n ear S o u th M im m s. W ith th e passing of th e Biological S ta n d a rd s A ct in 1975, the N a tio n a l B iological S ta n d a rd s B oard was estab lish ed and on 1 Ju ly 1976, w hen th e A ct cam e into force, th e new b o a rd took over fro m th e M .R .C . th e re sp o n sib ility for the m an ag em en t of the In stitu te .
O n his re tire m e n t in 1976 he m oved to the S ir W illiam D u n n School of P ath o lo g y in O x fo rd , once again as a D e m o n stra to r. D u rin g th is last spell of teach in g second year m edical stu d e n ts at O x fo rd , he reo rg an ized the practical course to teach as g reat a variety of te c h n iq u es as possible in the lim ited tim e available; and again in his lectures relied on his w ide practical ex perience to illu strate clearly and h u m o ro u sly th e elem en tary co n cep ts he w ished to im p a rt. H e finally re tire d from fu ll-tim e w ork in 1980 and w ith his wife, M ary, m oved to N o rth W ales to be n ear his d a u g h te r and h e r fam ily.
C om m ittee work
E v a n s's w orking years covered th e p erio d w hen p ro p h y la c tic vaccines against com m on infectious diseases w ere b ein g in tro d u c ed . As a m em b e r N um bers given in this form refer to entries in the bibliography at the end of the text. o f th e scientific staff and late r H e a d of th e B iological S ta n d a rd s C o n tro l L a b o ra to ry of th e M ed ical R esearch C ou n cil he w as involved in the la b o ra to ry te stin g o f th ese vaccines for safety a n d efficacy as well as in th e p la n n in g of field tria ls and a sse ssm e n t of th e ir resu lts. It w as in ev itab le th a t he sh o u ld be a m e m b e r of th e c o m m ittee s resp o n sib le for the su p e rv isio n a n d p la n n in g of th e w ork. H e was C h a irm a , th e W o rld H e a lth O rg a n iz a tio n (W .H .O .) E x p e rt P anel on Biological S ta n d a rd iz a tio n from 1956, th e J o in t C o m m itte e on V accin atio n and Im m u n iz a tio n , C e n tra l H e a lth Services he took an active p a rt in th e fo rm u la tio n of in te rn atio n a l re q u ire m e n ts for the m an u fa c tu re and co n tro l of n u m e ro u s vaccines such as those against sm allpox, polio m y elitis, d ip h th e ria , teta n u s, tu b erc u lo sis and m easles.
H onours
H e was elected a Fellow of th e Royal C ollege of P athologists in 1965 and was aw ard ed th e S te w a rt P rize for im p o rta n t w ork done on the origin and sp read of ep id em ic disease by the B ritish M edical A ssociation in 1968. H e was P re sid e n t of th e Society of G en eral M icrobiology 1972-75, was a p p o in te d C .B .E . in 1969 and k n ig h te d in 1977. In the sam e year he was aw ard ed the B u ch an an M edal of the Royal Society in recognition th a t his w ork h ad 'rev o lu tio n ized th e p ictu re of ch ild h o o d disease'. A n h o n o rary d o c to ra te was co n fe rre d on him by the U n iv e rsity of S u rrey in 1982.
S cien tific work
E v a n s's a p p o in tm e n t to the scientific staff of the D e p a rtm e n t of Biological S ta n d a rd s in 1940 d e te rm in e d his life-long in terest in im m u n iz a tio n against infective disease. U n d e r the d irectio n of Sir Percival H a rtle y he was resp o n sib le for d e te rm in in g th e effectiveness and safety of v arious vaccines and a n tise ra to be u sed in th e p ro p h y la x is o f ch ild h o o d fevers. H e w as co n c ern e d n o t only w ith th e lab o ra to ry w ork involved in vaccine d e v e lo p m en t, b u t w as an active m e m b e r o f th e co m m ittee s a p p o in te d by th e M .R .C . to p lan and su p erv ise th e clinical trials necessary to e sta b lish th e value o f th e vaccines b efo re th e ir in tro d u c tio n in to g eneral use. In th e b ib lio g ra p h y a p p e n d e d to th is m em o ir th e re are in clu d e d re p o rts to th e M .R .C . by th ese c o m m ittee s of w h ich E vans was a m e m b e r, usu ally as C h a irm a n or S e cretary . O f th ese re p o rts fo u r w ere co n c ern e d w ith field trials w ith m easles (75, 77, 82, 97) and one w ith d ip h th e ria (66). H e w as also one of eig h t m e m b e rs of th e N o r th u m b e r land C o m m itte e of E n q u iry on F o o t-a n d -M o u th D isease w h ich p r o d u ced a co m p re h en siv e a c co u n t o f th e disease in tw o p a rts (85).
Whooping cough
T h e first fo u r p a p e rs w ritte n in M a n c h e s te r w ith his chief, P ro fesso r H . B. M a itla n d , p ro v id e a very u seful in tro d u c tio n to E v a n s's later w ork on im m u n iz a tio n against w h o o p in g cough. In d e e d his in te re st in p e r tu ssis c o n tin u e d th ro u g h o u t his w ork in g life an d a q u a rte r of his p u b lic a tio n s deal w ith som e aspect of th is to p ic. T h e early p a p e rs show ed th a t th e h e a t-la b ile to x in of Bord. pertussis was q u ite sep arate fro m th e b acterial ag g lu tin o g en and c o u ld be titra te d by the fatal effect p ro d u c e d by in tra v en o u s in jectio n into g u in ea -p ig s, o r by th e local effects of in tra d e rm a l in jection in ra b b its (1). W h o o p in g cough convalescent sera h ad an tib a cte ria l a n tib o d y b u t failed to n e u tra liz e toxin. E vans & M a itla n d su g g ested th a t th e to x in m ig h t be resp o n sib le for illness in in fected h u m a n s as it caused th e d e a th of g u in ea -p ig s injected w ith living o r dead bacteria. T h e y also show ed, by ex am in atio n of sera fro m cases of w h o o p in g cough and c o n tro l sera, th a t th e ag g lu tin a tio n test by the slide m e th o d w as m o re sensitive th a n by tu b e test, and b o th w ere m ore sensitive th a n th e c o m p le m e n t fixation te c h n iq u e in d e te c tin g specific a n tib o d y (4).
T h e s e early p a p e rs w ritte n w ith M a itla n d also re p o rte d stu d ies of the rela tio n sh ip b etw een Bord. pertussis and Bord. bronchiseptica. S tra in s of Bord. bronchiseptica o b tain e d fro m th e lungs of n o rm a l g u in ea -p ig s w ere as v iru le n t as Bord. pertussis for g u in ea -p ig s and p ro d u c e d sim ilar lesions in these anim als a n d in a n a esth etize d m ice. T h e toxins of th e tw o o rg an ism s w ere sim ilar in heat lability. G u in e a -p ig s im m u n iz e d w ith Bord. pertussis w ere im m u n e to in tran asal in o cu latio n w ith Bord. bronchiseptica. H o w ev er, an tise ra p re p a re d in rab b its reached a h ig h er titre w ith hom o lo g o u s th a n w ith h e tero lo g o u s p re p a ra tio n s in ag g lu tin atio n and c o m p le m e n t fixation tests. C ro ss-a b so rp tio n tests w ith h eat-k illed o rg an ism s rem oved h om ologous a g g lu tin in b u t had no effect on hetero lo g o u s titre , su g gesting th a t each o rg an ism also had specific antigens (2). E vans later c o m p a red tw o stra in s of Bord.
, obtained from Dr Pearl Kendrick in America, with Bord. pertussis and Bord. bronchiseptica. The toxins were similar in their effects on guineapigs, mice and rabbits, and in their heat lability, and were non-antigenic in rabbits and guinea-pigs. Sera from immunized rabbits, when tested against the three organisms by agglutination and complement fixation tests, showed marked cross-reactivity suggesting that the three organisms belonged to the same group (5). Previous attempts to produce pertussis antitoxin by intravenous injection of the toxin into rabbits and guineapigs had failed, but Evans succeeded by injecting formolized toxin subcutaneously in rabbits. The rabbits were then actively immune to toxin injected into the skin. The sera contained agglutinin that could be removed by absorption leaving the antitoxin intact. Pertussis antitoxin neutralized pertussis, parapertussis and bronchiseptica toxins without differentiation (7).
In continued work on immunity to Bord. pertussis it was shown that rabbits immunized by injections of formolized toxic extracts of the organism had high titres of agglutinins as well as antitoxins, whereas animals immunized with toxic extract detoxified by heat, or bacteria killed by formaldehyde or heat, had high agglutinin titres but were not immune to toxin, and their sera failed to neutralize toxin. Evans suggested that any investigation into new types of pertussis vaccine should take account of the significance of toxin in infection, and that a vaccine that stimulated production of antitoxin in addition to antibacter ial antibody might give a more complete protection than that so far obtained (9). However, further experiments with rabbit sera gave little support to this suggestion (16). Rabbit immune sera, containing antibac terial antibody but no antitoxin, protected mice against intranasal infection as well as rabbit serum containing antitoxin and antibacterial antibody; absorption of both types of sera with heat-killed bacteria removed the protective power of both. Moreover, sera from 40 whooping cough patients and 17 sera from adults failed to neutralize toxin when tested by intradermal injection of mixtures into rabbits (23), thus confirming the earlier observations of Evans & Maitland (1). In further experiments, rabbits immunized with capsular material of Bord. pertussis did not show mouse-protective antibodies such as were present in the sera of rabbits immunized with washed bacteria, which led to the conclusion that the antigens of Bord. pertussis which produced agglutinating, complement fixing and mouse-protective antibodies were somatic rather than capsular (35).
The results of the first field trials of vaccines for the prevention of whooping cough were published in 1951 (34). The trials were organized by the Whooping Immunization Committee of the M.R.C. with S. P. Bedson as Chairman and Evans as Secretary. Ten trials were made in children under 2 years of age in five areas with vaccine from three sources: Sauer, Michigan and Glaxo. The field work was done by M edical O fficers of H e a lth a n d th e ir staffs an d th e re p o rt was p re p a re d by C o c k b u rn , E vans & K n o w e ld e n (34). T h e re w ere 3801 c h ild re n in the v accinated g ro u p and 3757 in th e co n tro l g ro u p w ho w ere given a n tic a ta rrh a l vaccines. W ith only a few ex cep tio n s th e re w ere no severe local o r general reactions. In all, 149 vaccin ated and 687 c o n tro l c h ild ren d eveloped pertu ssis; and th e disease was less severe and o f sh o rte r d u ra tio n in th e vaccinated th an in th e co n tro ls. A m o n g c h ild re n exposed to p e rtu ssis in th e ir ow n h o m es th e attack rates w ere 18.2% in th e v accin ated and 87.3% in the u n v accin ated . E ach b a tc h of vaccine gave su b sta n tia l p ro te c tio n b u t tw o b a tc h e s from th e M ich ig an D e p a rtm e n t of H e a lth gave a co n sid erab ly g re a te r degree of p ro te c tio n th a n the o th ers.
In th e course o f th e ir stu d ie s on im m u n ity in m ice in d u ce d by th e in jection of p ertu ssis vaccines, E vans and P erk in s fo u n d th a t, w ith in a few h o u rs of in jectin g vaccine, m ice w ere resista n t to in tra c e re b ra l in jectio n of a dose of Bord. p e r t u s s i s , w hich killed th e m ajo rit anim als. E ven 5 h o u rs after the in tra p e rito n e a l in jection of vaccine, 2 0 -6 0 % of m ice ch allenged in tra ce reb ra lly su rv iv ed , w hereas only one of 165 co n tro l m ice surv iv ed (41). W ith challenges given 1,3,6 and 10 days after vaccine th e re was a pro g ressiv e increase in th e p ro p o rtio n of surv iv o rs. N o a n tib o d ie s w ere d e m o n stra b le in th e sera of m ice at the tim es th ey w ere challenged. T h e im m u n ity was a p p a re n tly q u ite specific as o th e r vaccines given by the sam e ro u te h ad no p ro te c tiv e effect, b u t was in d e p e n d e n t of c irc u la tin g a n tib o d y . T h is in te rfe re n c e im m u n ity could be in d u ced by in tra ce reb ra l injectio n of vaccine given th re e h o u rs before the in tra ce reb ra l challenge dose (43). A fter one in tra p erito n e a l in jectio n of vaccine in m ice, m axim al im m u n ity was no t reached u n til 2 0 -4 0 days a fterw ard s w hen in te rfe re n c e im m u n ity had gone (45).
T h e resu lt of fu rth e r field trials, c arried o u t over several years in various areas of E n g lan d and W ales w ith 14 differen t batch es o f vaccine, en ab led a relation to be estab lish ed betw een the p ro te c tiv e value in ch ild ren and th e resu lts o f lab o ra to ry tests on th e sam e batch es (46). In the first series of trials b etw een O c to b e r 1948 and M a rc h 1951 B ritish vaccines w ere used; from early 1951 to m id-1954, b o th B ritish and A m erican vaccines w ere used. T h e re w ere no u n v accin ated co n tro l ch ild ren b u t in som e areas the incidence of w h o o p in g cough in u n v a c cin ated siblings was c o m p a red w ith th a t in the v accinated c h ild ren in th e sam e fam ilies exposed to w ho o p in g cough. A total of 28 799 c h ild ren w ere follow ed up for an average of tw o years after vaccination and the p ro tectiv e effect was m ainly d e te rm in e d from hom e ex posure attack rates. T h e nine b atch es of vaccine used in the first series of trials w ere ra th e r poor and had been m ade from the sam e stra in of Bord.
, w hich h ad been s u b c u ltu re d repeatedly. T h e five vaccines used in the second series of trials gave su b sta n tia l p ro te c tio n and had been m ade from a m ix tu re of four, six or seven strain s s u b c u ltu re d on very few occasions before being p reserv ed by freeze drying; all vaccines in the second series had b een k illed a n d p re se rv e d w ith th io m ersa la te. F ie ld stu d ie s show ed th a t th re e vaccines (V 9, V I 0, V I 2), m ad e in B rita in fro m stra in s isolated in B rita in , w ere as effective as th e referen ce vaccine (V8) m ad e w ith A m e ric an stra in s in th e M ic h ig a n D e p a rtm e n t of H e a lth . T h e vaccines w ere also te ste d for th e ir p o w er to p ro te c t m ice ag ain st in tra c e re b ra l in fe c tio n s and fo r a g g lu tin in p ro d u c tio n in m ice and c h ild re n . T h e r e was a c o rre la tio n b e tw e en th e p o w er to p ro te c t c h ild re n a n d th e th re e lab o ra to ry tests. O f th ese th e in tra c e re b ra l challenge te st on the m ouse w as c o n sid e re d m o st satisfacto ry on th e evidence available. V accine V I 2 w as d e sig n a ted th e B ritish sta n d a rd vaccine and p rese rv ed by freeze d ry in g in d e x tra n ( 6 0 g T 1). In a p a p e r given at an in te rn a tio n a l congress on s ta n d a rd iz a tio n in R om e (47), E vans gave a su m m a ry of th e resu lts of th e tria ls d e sc rib e d above an d su g g ested th a t th e m o u se -p ro te c tio n test was th e b e st la b o ra to ry m ea su re of th e p o ten cy o f p e rtu ssis vaccines. H o w ev er, b ecause of th e in te rfe re n c e effect, m ice sh o u ld be teste d 28 days a fte r th e im m u n iz in g dose of vaccine, once stable im m u n ity has been e sta b lish e d , an d n o t a fter 10-14 days, w hen in te rfe re n c e im m u n ity is w aning.
Tetanus
E v a n s 's w ork on te ta n u s began w ith a stu d y of a n tito x in responses of 81 h e a lth y v o lu n te e rs a fter a course of injections of teta n u s form ol toxoid (8): tw o doses of 1 m l w ith an in terv al of nin e w eeks b etw een doses. Blood sam ples for estim a tio n of an tito x in c o n te n t w ere collected before th e first in jectio n of toxoid, im m ed iately before th e second and 17 w eeks after the second dose o f toxoid. B efore im m u n iz a tio n none of th e v o lu n te e rs had as m u ch as 0.01 of a u n it p e r m l of seru m . N in e w eeks after the first toxoid in jectio n , 31 of 53 sera ex am in ed h ad m o re th a n 0.01 u n it and 22 had less th a n 0.01 u n it of an tito x in . S ev en teen w eeks after the second injection of tox o id all 70 ex am in ed had m ore th a n 0.01 u n it, 59 had m ore th a n 0.1 u n it and 19 m ore th an 1 u n it. T h e an tito x in level was su b stan tially m ain ta in e d for 10 m o n th s after th e second injection. A t this tim e a th ird injectio n of toxoid was given to 16 v o lu n teers. T h is resu lte d in a large and rap id increase in an tito x in level in se ru m and 18 m o n th s after this th ird in jection the a n tito x in level was m u ch h ig h er th an after tw o injections of toxoid (13).
C o m b in ed active and passive im m u n iz a tio n against d ip h th e ria was k n ow n to be effective and th is m eth o d was tested by E vans and his co llab o rato rs against teta n u s in in ju re d p erso n s a tte n d in g the casualty d e p a rtm e n ts in tw o L o n d o n h o spitals. T h e y w ere given 1500 u n its of teta n u s an tito x in in tra m u sc u la rly in one arm and 0.5 m l of ad so rb ed toxoid in tra m u sc u la rly in the o th e r (69). T h e p atien ts re tu rn e d 6 weeks later w hen a seru m sam ple was taken and a second in tra m u sc u la r injection of ad so rb ed toxoid given. A final sam ple of seru m was taken 2 weeks after the second dose of toxoid. T h e results from 82 persons who had n o t b een p rev io u sly im m u n iz e d against te ta n u s w ere in c lu d e d in th e analysis. T w o w eeks afte r th e second dose of to x o id all b u t one p a tie n t had m o re th a n 0.02 u n it of a n tito x in p e r m l o f se ru m an d 69 (8 4 % ) h ad a n tito x in titre s of 0.5 u n it/m l or m o re. I t w as c o n c lu d e d th a t s im u lta neo u s active and passive im m u n iz a tio n ag ain st te ta n u s by u sin g a d so rb e d toxoid w as a p ractical p ro p o sitio n . O n th e basis o f th ese stu d ie s E vans and his colleagues d rew up a c o m p re h en siv e p lan for th e p re v e n tio n of te ta n u s in th e w o u n d e d (76). T h e im m u n iz a tio n to be given d e p e n d e d on p rev io u s h isto ry o f im m u n iz a tio n against te ta n u s, th e n a tu re of th e w o u n d , its age an d th e p o ssib ility o f a d e q u ate su rgical to ilet. W o u n d s th a t w ere m o re th a n 6 h o u rs old w ith c o n sid e rab le tissu e dam age in p e rso n s w ho h ad n o t h ad a c o m p lete co u rse of to x o id m ig h t re q u ire a n tib io tic tre a tm e n t for som e days, an d a n tito x in by su b c u ta n e o u s in jectio n only if th e w o u n d w ere th o u g h t to c arry a specially h ig h risk of te ta n u s. T h is re s tric te d use o f a n tito x in was re c o m m e n d e d w h en th e a n tito x in available w as of e q u in e orig in as th is c a rrie d th e risk of h y p e rse n sitiv ity reactio n s. W ith th e availability o f h u m a n te ta n u s im m u n o g lo b u lin , E vans and his colleagues su g g ested th a t an in tra m u s c u la r in jectio n o f 250 u n its m ig h t be relied on to give a se ru m c o n c e n tra tio n of a n tito x in above 0.01 u n it/m l for a b o u t 4 weeks; th is, to g e th e r w ith active im m u n iz a tio n w ith spaced in jectio n s of a d so rb e d to x o id , w ould suffice for th e tre a tm e n t o f w o u n d s ca rry in g a risk of te ta n u s in p e rso n s w ho h ad n o t b een p rev io u sly im m u n iz e d or w hose h isto ry of im m u n iz a tio n was u n k n o w n (95).
Cl. welchu and other Clostridia producing gas gangrene
E v a n s 's w ork on these b a c te ria b egan w hen he jo in e d Percival H a rtle y in th e D e p a rtm e n t of Biological S ta n d a rd s in th e N a tio n a l In s titu te for M edical R esearch. H is first tw o p ap ers (10, 14) w ere c o n c ern e d w ith th e relative im p o rta n c e in the p ro d u c tio n of gas g an g ren e in th e g u in ea -p ig of th e a lp h a -to x in , th e th e ta -h a e m o ly sin and th e h y a lu ro n id ase p ro d u c e d by stra in s o f Cl. welchii. F o u r stra in s o f vary in g viru len ce w ere used; alp h aa n tito x in p ro te c te d against all strain s b u t a se ru m c o n ta in in g a n ti-th e tahaem o ly sin b u t little a lp h a -a n tito x in h ad no such effect (10). S im ilar tests w ith se ru m co n ta in in g a n ti-h y a lu ro n id a se b u t no a lp h a -a n tito x in failed to p ro te c t g u in ea -p ig s against e x p e rim e n tal g as-g an g ren e infectio n (14). It w as co n clu d ed th a t, a lth o u g h a n tib o d ie s to at least th re e an tig en s ela b o rate d by Cl. welchii type A could be p re se n t in an tisera p re p a re d against filtrates of c u ltu re s of th is org an ism , it was th e a lp h a -a n tito x in th a t w as of im p o rta n c e in th e p ro te c tio n against in fectio n ex p erim en tally p ro d u c e d in g u in ea -p ig s by Cl. welchii ty p e A.
In A p ril 1940 a req u e st was received fro m th e H e a lth O rg an izatio n of th e L eague of N a tio n s e n q u irin g w h e th e r th e M .R .C . w ould be p re p a re d to su p p ly th e In te rn a tio n a l S ta n d a rd s for the a n tito x in s and an tisera to la b o ra to rie s p rev io u sly s u p p lie d by th e S ta te S e ru m In s titu te , C o p e n h agen. S ince c o n sid e ra b le stocks o f th e In te rn a tio n a l S ta n d a rd s w ere m a in ta in e d at H a m p s te a d , th e M .R .C . readily acceded to th is re q u e st, a n d also d e c id e d to p re p a re rep la c e m e n t s ta n d a rd s to m eet a possible in crease in d e m a n d . T h e m ate ria l for th e p re p a ra tio n of the th re e sta n d a rd s for Cl.perfrmgens, Cl. septicum an d Cl. oedematiens an tito resp ectiv ely w as p ro v id e d by th e W ellcom e P hysiological R esearch L a b o ra to rie s , B eck en h am . T h e a n tito In a s tu d y on th e value of s ta n d a rd g a s-g a n g ren e an tito x in s in the tre a tm e n t o f e x p e rim e n tal gas g an g ren e in g u in ea -p ig s, th e an tito x in s w ere given in tra v en o u sly at 6, 16, 20 a n d 24 h o u rs a fter infection (18). T h e in fe c tin g doses o f Cl. welchii, Cl. septicum and Cl. oedematiens given in tra m u sc u la rly w ere equal to 1000 lethal doses: 25 u n its of Cl. welchii a n tito x in given afte r 6 h o u rs gave good p ro te c tio n , w ith no im p ro v e m e n t w h en 250 o r 2500 u n its w ere used. T h e sam e doses given a fter 20 h o u rs gave som e p ro te c tio n , b u t at th is stage lesions w ere already well ad v an ced . W ith Cl.
o
e d e m a t i e n s
, 25 u n its of a n tito x in failed to save any anim als w h e n given afte r 6 o r 16 h o u rs, b u t 2500 u n its saved all anim als. T h e sam e dose given a fter 24 h o u rs failed to p ro lo n g the life of any. Cl. septicum p ro d u c e s m o re rap id disease, w hich killed co n tro ls in 20-26 h o u rs. T w e n ty -fiv e u n its of an tito x in given a fter 6 h o u rs failed to save any g u in ea -p ig s, 250 u n its saved 3 of 6 and 2500 u n its saved all. N o anim als w ere saved w hen a n tito x in was given after 16 h o u rs.
In fu rth e r a tte m p ts to d e te rm in e the relative im p o rta n c e of alphato x in , th eta -h a e m o ly sin and h y alu ro n id ase in th e path o g en icity of 1951 Br. dent. J . 91, 197-198) , 27 w ere chosen at ra n d o m fo r ex am in atio n by E vans & P ro p h e t (33). All w ere type A, v iru le n t fo r th e g u in ea -p ig , p ro d u c e d a lp h a -to x in and an enzym e th a t d isin te g ra te d d e n tin e (33).
Poliomyelitis
As h ead of the Biological S ta n d a rd s C o n tro l L a b o ra to ry o f the N atio n al In s titu te for M edical R esearch, E vans was resp o n sib le for d e te rm in in g th e safety and an tig en ic p o ten cy of polio m y elitis vaccine of th e Salk type p re p a re d in th is c o u n try . T h e m e th o d s w ere based on those used in A m erica, w here polio m y elitis vaccine was first p re p a re d . T h e Salk vaccine w as a fo rm o lized su sp en sio n of th e th re e ty p es of polio m y elitis v iru s grow n in m onkey kidney tissue c u ltu res. As th e v iru s strain s from w hich the vaccine was p re p a re d w ere v iru le n t, it was essential th a t no viru s su rv iv ed th e fo rm alin tre a tm e n t. In the final tests th e vaccine was ex am in ed for th e p resen ce of live v iru s by the in o cu latio n of cell c u ltu re s and of m onkeys, and for its antigenic activity in m onkeys (49). F ro m each b a tc h of fo rm o lized vaccine, n e u tra liz ed by so d iu m m e ta b isu lp h ite b u t w ith o u t p reserv ativ e, 3.51 was o b tain e d fro m th e m a n u fa c tu re r and dialysed in 500 m l q u a n titie s against H a n k 's so lu tio n before in o cu latio n into b o ttles of m onkey kidney tissue c u ltu res, w hich w ere th e n in cu b a ted at 37 °C for 21 days. T h e c u ltu re s w ere exam ined m icroscopically tw ice w eekly for cy to p a th ic changes. F o r the safety test in m onkeys, at least 400 m l of each b a tc h of vaccine was su p p lie d by the m a n u fa c tu re r and was tested for the p resen ce of live po lio v iru s by injectin g it into rh esu s o r cynom olgus m onkeys by v arious ro u tes. T h e m onkeys w ere ob serv ed for 24 to 28 days after in jection of vaccine and co rtiso n e, and signs of d y sfu n c tio n reco rd ed . B lood w as taken fro m each anim al at 3 or 4 day in terv als for the first tw o w eeks and th e sera teste d in cell c u ltu re s for the presence of p o liovirus. E ach b atch of vaccine was teste d for an tig en ic activity in a g ro u p of 12 rh esu s m onkeys th a t w ere each in jected at w eekly in terv als w ith 1 m l of u n d ilu te d vaccine fro m final co n tain ers, and b led seven days after the th ird dose. T h e in d iv id u al sera w ere titra te d for n e u tra liz in g an tib o d ies to each o f th e th re e types of p oliovirus. T h is p ro ce d u re was later replaced by a sim p ler schedule.
T h e re was clearly a n eed for sta n d a rd an tisera to each of the th re e poliom yelitis viru s types to enable the n e u tra liz in g p o ten cy of o th e r sera to be ex p ressed in term s of th e sta n d a rd , and to allow a valid c o m p a ri son to be m ade betw een the resu lts o b tain ed by different w orkers. C o n se q u e n tly P erk in s and E vans p re p a re d m onospecific an tisera to each ty p e of poliom yelitis virus in rh esu s m onkeys by im m u n iz a tio n w ith live virus su sp en sio n s p rep a re d in m onkey kidney cell cu ltu res. F o r each type the high titre serum was d ilu ted in aqueous d e x tra n (60 g 1 " x) so lution to give a n e u tra liz in g a n tib o d y titre of the o rd er of 500-1000. A p p ro x im ately 1 1 of each d ilu ted serum was o b tain ed and was d is trib u te d in 1 m l volum es in glass a m p o u le s and freeze d rie d . F ive lab o ra to rie s took p a rt in a c o lla b o ra tiv e stu d y of th e p o ten c y of th ese th re e sta n d a rd sera and 18 o th e r rh e su s sera. T h e n e u tra liz a tio n tests w ere m ad e in m o n k ey kidney c u ltu re s . C lose a g re e m e n t w as o b ta in e d b e tw e en the d ifferen t la b o ra to rie s w h e n th e ty p e 1, 2, or 3 n e u tra liz in g p o ten cies w ere d e te rm in e d w ith referen ce to fre e z e -d rie d p re p a ra tio n s of an tisera. It was th ere fo re d e c id e d to esta b lish th e th re e fre e z e-d rie d p re p a ra tio n s o f an tise ra as B ritish S ta n d a rd p o lio m y elitis an tise ra ty p es 1, 2 and 3, and to assign to each a value of 10 u n its p e r am p o u le (55).
In h is lec tu re on 'V accin atio n against p o lio m y e litis' in th e series on th e scientific basis o f m ed icin e (58), E vans o u tlin e d the m e th o d of p re p a ratio n of p o lio m y elitis vaccine and discu ssed various causes for v ariatio n in an tig en ic p o ten cy , in c lu d in g v a ria tio n in the tissu e c u ltu re used to grow v iru s, th e n a tu re of th e c u ltu re m e d iu m , the m e th o d of in activ atin g th e v iru s, th e te m p e ra tu re of in activ atio n and th e te c h n iq u e of filtratio n used h alf-w ay th ro u g h th e in activ atio n p erio d . In testin g the antigenic p o ten cy of vaccine in the lab o ra to ry , 12 rh esu s m onkeys w ere each given th re e in jectio n s of 1 m l at in terv als of one w eek. B lood sam ples taken 7 days after th e th ird in jectio n w ere tested to d e te rm in e th e co n c en tra tio n of a n tib o d ie s to all th re e types of p o lio v iru s. D ilu tio n s of seru m w ere m ixed w ith a c o n sta n t a m o u n t of live v iru s, the m ix tu re s held at 37 °C for 3 h o u rs and th e n in o cu la te d in to tissue c u ltu res, w h ich w ere exam ined 6 days late r to d e te rm in e th e h ig h est d ilu tio n of th e se ru m th a t n eu tralized the viru s. T h is m e th o d was n o t the b est desirable, and E vans again stressed th e need for sta n d a rd an tisera w h ereb y sera u n d e r test, in c o m p a riso n w ith th e s ta n d a rd sera, could be evaluated in u n its. V accines fo u n d to have good titre s by lab o rato ry tests in m onkeys also gave good resu lts w hen tested in schoolboys. T h re e doses of vaccine w ere rec o m m e n d e d : a m o n th b etw een the first and second doses w ith th e th ird (booster) dose 6-12 m o n th s later. E vans insisted th a t vaccines sh o u ld be such th a t th ey w ould give a p rim a ry respo nse su b stan tial en ough to e n su re th a t all su bjects w ould give a b o o ste r response to th e th ird in jectio n . T h e relation of vaccination against poliom yelitis to o th er im m u n iz a tio n p ro ce d u re s was co n sid ered at som e length. E vans a d vocated th a t p re g n a n t w om en sh o u ld be given tw o inoculations of inactiv ated polio vaccine so th a t the n ew b o rn child w ould receive passive im m u n ity to p o liovirus, u n d e r cover of w hich th re e doses of trip le vaccine (d ip th e ria, teta n u s and p ertu ssis) could be given d u rin g the first six m o n th s of life, to be follow ed at 8 and 9 m o n th s w ith 2 doses of polio vaccine, w ith a b o o ster dose at 20 m o n th s and a b o o ster dose of trip le vaccine at 2 to 3 years of age. T h is is a subject to w hich E vans re tu rn e d (56): he p ro p o sed an altern ativ e schem e as p reg n a n t w om en m ig h t be relu c ta n t to accept polio vaccination. Because m ost deaths from p ertu ssis occur in the first year of life, w hile d eath s from d ip h th e ria and tetan u s occur later, he reco m m en d ed 2 or 3 doses of p ertu ssis vaccine betw een 2 and 5 m o n th s of age, 2 doses of polio vaccine at 8 -1 0 m o n th s, follow ed by a re in fo rc in g dose at 2 0 -2 4 m o n th s, th e n 2 doses of d ip th e ria -te ta n u s at 2 years and a re in fo rc in g dose at 4 -5 years. E vans th o u g h t th a t serious c o n sid e ra tio n m ig h t be given to in c o rp o ra tin g an a lu m in iu m a d ju v a n t such as a lu m in iu m h y d ro x id e or p h o sp h a te in po lio m y elitis vaccine, a lth o u g h , if it w ere to be used, th e level o f a d ju v a n t sh o u ld be k ep t to a m in im u m . T h is , how ever, w as u n n e c essa ry w h en S a b in 's live a tte n u a te d vaccine w as in tro d u c e d . In his c o n trib u tio n to th e 7th S y m p o siu m of the E u ro p e a n A ssociation o f P o lio m y elitis and A llied D iseases, E vans c o n sid e re d th e relative m e rits of S a lk 's in ac tiv a ted vaccine and S a b in 's live a tte n u a te d vaccine (61). I t w as claim ed th a t S ab in vaccine p ro d u c e d an in te stin a l resistan ce, w h ich led to th e d isa p p e a ra n c e of th e c a rrie r state; b u t a p p a re n tly th e w id e sp re a d use o f Salk ty p e vaccine in S w ed en h ad also red u c e d th e c a rrie r rate. A lth o u g h b o th vaccines are h ig h ly effective in re d u c in g th e in cid en ce o f p a ra ly tic polio m y elitis it seem ed likely th a t, because o f the ease of a d m in istra tio n , S ab in vaccine w o u ld replace Salk and th is has p ro v ed to be so. O ne d isad v an tag e of S a b in -ty p e vaccine is th a t it m ay c o n ta in live sim ian v iru ses d e riv e d fro m th e m o n k ey kidney cells u sed in its p re p a ra tio n . In B rita in , w h en th e reg u la tio n s for th e m a n u fa c tu re of live vaccine w ere d raw n u p , it w as sta te d th a t vaccine sh o u ld n o t be acceptable for use in m an u n less it was free fro m all living e x tra n eo u s m ic ro o rg a n ism s-a pro v iso th a t E vans w o u ld have liked to have a d o p te d for all vaccines used in m an. In th is c o m m u n ic a tio n E vans again m ade a plea for th e e sta b lish m e n t o f In te rn a tio n a l S ta n d a rd P o lio m y elitis A n tise ra o f agreed un itag e, against w h ich th e p o ten cy of o th e r sera co u ld be d e te rm in e d by a sta n d a rd te c h n iq u e . In a later in te rn a tio n a l co llaborative stu d y of th e assay of th e p o ten cy of polio m y elitis an tisera c o o rd in a te d by the W o rld H e a lth O rg an izatio n , it is sta te d th a t th e referen ce sera th e n available w ere b ein g rep laced by in te rn a tio n a l sta n d a rd p re p a ra tio n s (67).
In a leading article in th e British M edical Journal (68) E vans suggested th a t 'w ith p ro p e r safeguards in its m a n u fa c tu re and use oral p oliom yelitis vaccine offers th e g rea test p o ssib ility of co m p letely e lim in a tin g polio v iru s as a h u m a n p a th o g e n '. In d iscu ssin g the lab o rato ry co n tro l of Salk vaccine p o ten cy E vans in sisted th a t th e final anim al test of im m u n iz in g activity sh o u ld be m ade in c o m p a riso n w ith a reference vaccine th a t h ad b een show n to give good p ro te c tio n in m an (64). In an article on oral po lio m y elitis vaccine in 1961, he p o in te d o u t th a t th e incidence of polio m y elitis was in th a t year n o t in co n sid erab le in spite of th e use of Salk v accination since th e sp rin g of 1956 (65)-n o t th a t th e Salk vaccine was ineffective in p ro te c tin g those w ho h ad received it, b u t th e scale on w hich it h ad b een given had n o t been sufficient to en su re im m u n ity o f the h erd .
T h e S ab in a tte n u a te d oral vaccine is m o re aceptable to the p u b lic and p ro d u ce s n o t only an tib o d y im m u n ity b u t also resistance of the g u t to infection. T h u s w hen given on a m ass scale it can elim inate w ild p o lio v iru se s fro m th e p o p u la tio n . In tria ls c o n d u c te d by th e P u b lic H e a lth L a b o ra to ry S ervice a c o m p a riso n , b ased on p ro d u c tio n o f a n ti b o d y a n d v iru s co lo n iz atio n of th e g u t, w as m ad e o f th e effectiveness of th re e d iffe re n t im m u n iz in g schem es.
T h e resu lts show ed th a t one dose of triv a le n t vaccine w as n o t sa tisfa c to ry b u t th a t good resu lts w ere o b ta in e d w ith e ith e r th re e doses of triv a le n t vaccine at fo u r w eek in te rv als or th re e doses o f m o n o v a le n t vaccine at fo u r w eek in te rv als in th e o rd e r ty p e 1, ty p e 3 a n d ty p e 2. O n th e g ro u n d s of sim p lic ity and ease of a d m in is tra tio n , th e P u b lic H e a lth L a b o ra to ry S ervice stro n g ly re c o m m e n d e d th e sch em e c o m p risin g th re e doses of triv a le n t vaccine. M a n y p a p e rs w ere p u b lis h e d by m e m b e rs of th e C o n tro l L a b o ra to ry 's staff on d ifferen t asp ects o f p o lio m y elitis vaccines on w h ich E v a n s 's nam e co u ld well have a p p e a re d . H e felt th a t a lth o u g h he had h e lp e d , g u id ed and often was actu ally en g ag ed in som e of th e field w ork his staff sh o u ld take th e m ain c re d it for th ese p u b lic a tio n s.
B .C .G .
In 1957 th e M .R .C . set u p a c o m m ittee , w ith D av id E vans as C h a irm a n , on th e sta n d a rd iz a tio n o f fre e z e -d rie d B .C .G . tu b erc u lo sis vaccine w h ic h w as to replace th e sta n d a rd liq u id vaccine p re p a re d at th e S tate S e ru m In s titu te in C o p e n h a g e n . T h e fre e z e-d rie d vaccine used in th e tria ls w as p re p a re d by G laxo L a b o ra to rie s L im ite d . T h e liq u id and fre e z e -d rie d vaccines to be used in field trials on M id d lesex sch o o lch il d re n w ere teste d in th e lab o ra to ry for th e ir c o n te n t of viable bacteria. T h e viable c o u n t of th e liq u id vaccine was a little h ig h e r th a n th a t of the fre e z e -d rie d p re p a ra tio n . A fter im m u n iz a tio n , ra th e r m ore of those sch o o lc h ild ren given liq u id vaccine gave a positive reaction to 3 tu b e r culin u n its ( T .U .) th a n th o se given th e fre e z e-d rie d p re p a ra tio n , and th e v a ccin atio n lesion was on the w hole slightly larger. H o w ev er th e resu lts of v a ccin atio n w ere satisfacto ry w ith b o th . All those w ho failed to react to 3 T .U . a fter vaccin atio n w ere positive to 100 T .U . (50). In the second re p o rt to th e M ed ical R esearch C o uncil by the C o m m itte e on S ta n d a rd i zation of F reeze D rie d B .C .G . V accine, th e sta b ility of the vaccine was teste d u n d e r differen t c o n d itio n s (60). F re e z e -d rie d vaccine kep t at room te m p e ra tu re had a low viable c o u n t w hen tested for up to 120 weeks. A fter a y e a r's storage at 37 °C no viable b acteria w ere d etected in u n d ilu te d p re p a ra tio n s of th re e b atch es of freeze-d ried vaccine w ith an initial titre of 2.3 to 5.8 x 106. It was co n clu d ed th a t B ritish freeze-d ried vaccine was a successful vaccine against tu b ercu lo sis, as show n by the con v ersio n of tu b e rc u lin negative sch o o lch ild ren to tu b e rc u lin positive. T u b e rc u lin reactivity was p ro d u c e d at a sim ilar rate and m ain ta in e d to the sam e e x te n t as w ith liq u id D a n ish vaccine. S torage of freeze-d ried vaccine at 4 °C for up to one year gave satisfactory results, b u t storage at 23 °C for 6 m o n th s was associated w ith a decline in activity. T h e results su g g ested th a t b atch es of fre e z e -d rie d vaccine w ith viable c o u n ts g rea ter th a n 1 x 106/m l p ro d u c e d a d e q u ate tu b e rc u lin sen sitiv ity . B atches w ith viable c o u n ts of 4 to 7 x 106 have been show n to p ro d u c e a h igh degree of tu b e rc u lin sen sitiv ity and an excep tio n ally low in cid en ce of u n to w a rd v accination reactions. B ecause of the active p a rt he played in th o se tests of fre e z e-d rie d and liq u id vaccines o f B .C .G . E vans was in v ited to act as P re sid e n t at th e In te rn a tio n a l S y m p o siu m on B .C .G . V accine at F ra n k fu rt (M ain ) in 1970 (90) .
Measles
T h e p a p e rs dealing w ith m easles listed in th e b ib lio g ra p h y w ere m ostly re p o rts of th e M easles V accine C o m m itte of the M edical R esearch C ouncil. T h e tw o ex cep tio n s w ere leading articles in th e British M edical Journal c o n trib u te d by E vans (78, 83). E vans was S e c re tary and th en C h a irm a n of th e M easles V accine C o m m itte e , w hich was rep o n sib le for o rg an izin g the vaccine trials and p re p a rin g th e re p o rts s u b m itte d to the M edical R esearch C ouncil (75, 77, 82, 89, 97) . T h e field trials of the m easles vaccines in vario u s p a rts of E n g la n d and W ales re q u ire d the c o o p eratio n of M edical Officers of H e a lth and th e ir staffs, m edical p ra c titio n e rs and th e p a re n ts of th e c h ild re n to w hom th e vaccines w ere a d m in iste re d . A p relim in ary in q u iry was m ade to test th e reactio n of c h ild ren to th e a tte n u a te d live m easles vaccine and to killed vaccine follow ed by live, and to assess the serological response to these vaccines (75). P ractically all the ch ild ren tak in g p a rt in th e in q u iry w ere 10-18 m o n th s old. T h e reactions as d e te rm in e d by rise of te m p e ra tu re w ere g rea ter after live vaccine th a n after killed vaccine follow ed by live. T h e an tib o d y responses w ere satisfactory w ith b o th form s of im m u n iz a tio n . T h e resu lts of a clinical trial of these tw o vaccine schedules on som e th o u sa n d s of c h ild ren w ere rep o rte d by the M easles V accine C o m m ittee six m o n th s after vaccination (77). It was fo rtu n a te for the p u rp o se of the trial th a t m easles was fairly w id esp read in E n g lan d d u rin g th a t perio d . T h e incidence of m eales was 12 p er 1000 in the g ro u p given killed follow ed by live vaccine, 16 p e r 1000 in the live vaccine g ro u p and 94 p er 1000 in the co n tro l u n v accin ated g ro u p . T h e attack rates in those exposed at hom e w ere 9 % , 6% and 83% respectively in the th ree g ro u p s. In the second re p o rt to the M edical R esearch C ouncil by the M easles V accine C o m m itte e on the clinical trial of live vaccine given alone and live vaccine preced ed by killed vaccine, the resu lts 2 years and 9 m o n th s after vaccination w ere p rese n ted . M o re th an 36 000 ch ild ren aged 10 m o n th s to 2 years took p art. T h e resu lts of p ro te c tio n for this trial w ere re p o rte d for tw o tim e periods: for the first 9 m o n th s and for th e w hole perio d (82). A fter the first 9 m o n th s th e vaccines gave 85 and 84% p ro te c tio n respectively and m ild cases, w hen they occu rred , w ere m ore com m on am ong the vaccinated. In the su b seq u e n t 2 year follow -up the confirm ed cases of m easles p e r 1000 in th e th re e g ro u p s w ere 27, 13 and 222-p ro te c tio n rates o f 88 a n d 9 4 % . W h e n th e resu lts w ere analysed for th e first 9 m o n th s an d for th e s u b s e q u e n t 1 and 2 years th e re w as no w an in g of im m u n ity an d live vaccine alone was slightly b e tte r th a n killed follow ed by live. T h e use of live vaccine alone gave a su b sta n tia l degree of p ro te c tio n th a t was w ell m a in ta in e d d u rin g th e p e rio d of th e trial, w hich co v ered tw o ep id em ics. T h e th ird re p o rt o f th e M easles V accine C o m m itte e (89) show ed th a t p ro te c tio n given by th e vaccines was m a in ta in e d for a f u rth e r tw o years b e y o n d th e p e rio d covered by the second re p o rt. T h e fo u rth re p o rt (97) rec o rd e d the fo llo w -u p of 5000 c h ild re n given a single dose of live a tte n u a te d m easles vaccine w hen aged 10 m o n th s to 2 years. T h e y show ed a h ig h level o f p ro te c tio n in c o m p a riso n w ith an u n v a c cin a te d g ro u p . P ro te c tio n h ad been m ain ta in e d for 12 years a n d th e re was no evidence th a t a fu rth e r injectio n of vaccine was n e e d ed . T h is has b een co n firm ed by parallel serological stu d ies on a sam ple of th e c h ild ren .
Contribution to the control of animal diseases
E v a n s 's in v o lv em en t in the stu d y of v e te rin a ry p ro b le m s dated from his a p p o in tm e n t to th e g o v e rn in g bod y of the A nim al V irus R esearch In s titu te at P irb rig h t in 1964. As P irb rig h t had b een for m any years the c e n tre for research on fo o t-a n d -m o u th disease, it was n o t su rp risin g th a t A fter c o n sid e ratio n of co n tro l m easures used in G re a t B ritain and elsew here th ere is a discussion of fu tu re policies for G re a t B ritain. P a rt tw o of th e re p o rt is largely given over to detailed a rra n g e m e n ts and rec o m m e n d e d im p ro v e m e n ts for dealing w ith fu tu re o u tb reak s. T h e conclusions and reco m m e n d a tio n s in c h a p te r 5 occupy 13 pages and a list of those in B ritain and ab ro ad w ho gave w ritte n and oral evidence to the c o m m ittee is given in A p p en d ix 1 of the re p o rt. F o u r co u n tries in E u ro p e , fo u r in S o u th A m erica and the U n ite d S tates w ere visited by the c o m m ittee and the g o v e rn m e n ts o f 37 co u n tries su b m itte d w ritten evidence.
In Ja n u a ry 1971 E vans was invited by th e Jo in t R acing Board: 'T o u n d e rta k e a stu d y of and re p o rt on p ro b lem s, practices and p ro ced u res c o n n ected w ith the im m u n izatio n of horses against in flu en za' (91). A p p e n d ix B of E v a n s's rep o rt lists 40 people at hom e and abroad w ho w ere c o n su lted d u rin g the stu d y and nine estab lish m en ts visited: th ree in E n g la n d , th re e in F ra n ce and one each in G en ev a (W .H .O .), W est G e rm a n y and H o llan d . In th e m ain section o f th e re p o rt E vans d iscusses th e disease p ro d u c e d by tw o stra in s of v iru s, A eq u i 1 and A eq u i 2. N o vaccine w as b ein g p re p a re d in B rita in at th e tim e o f w ritin g b u t fo u r w ere b ein g im p o rte d u n d e r licence fro m th e M .A .F .F . fro m firm s in H o llan d , th e U .S .A ., F ra n ce a n d G e rm a n y . T h e efficacy of these vaccines was diffuclt to te st in large n u m b e rs of horses. T h e h a e m a g g lu tin in titre s of vaccines m ig h t be som e in d ic a tio n o f th e ir p o ten cy , b u t E vans su g g ested th a t tests sh o u ld be dev elo p ed in sm all lab o ra to ry anim als to be c o m p a red w ith a n tib o d y p ro d u c tio n in horses. In general it was believed th a t th e vaccines in d u ce d som e degree of p ro te c tio n a n d th a t side reactio n s w ere in fre q u e n t, b u t th ese view s w ere n o t s u p p o rte d by statistically c o n tro lle d o b se rv a tio n s. T h e follow ing rec o m m e n d a tio n s w ere m ade:
(1) a lo n g -te rm p ro je c t for in v estig a tin g e q u in e re sp ira to ry diseases and th e effect of vaccin atio n against influenza sh o u ld be instig ated ;
(2) an in v estig atio n into m eth o d s of assaying th e p o ten cy of influenza vaccine sh o u ld be u n d e rta k e n w ith a view to esta b lish in g a m in im u m re q u ire m e n t for potency; (3) vaccin atio n against e q u in e influenza sh o u ld be on a v o lu n ta ry basis; (4) th e rec o m m e n d a tio n s c o n ta in ed in th is re p o rt sh o u ld be review ed from tim e to tim e in th e light o f th e resu lts o b tain e d fro m th e suggested in v estigations.
O f E v a n s's association w ith th e H o rse ra c e B ettin g L evy B oard S ir W illiam H e n d e rso n , F .R .S ., has w ritte n (1984):
'A b o u t 1970, D a v id 's advice w as so u g h t by th e th e n C h a irm a n of th e B oard (L o rd W igg) on th e p ro b le m of e q u in e influenza in spite of th e B oard having a V e te rin ary A d v isory C o m m ittee. W igg th en in sisted th a t D av id becam e a m e m b e r of the C o m m itte e in 1972. T h is w as u n d e r c irc u m stan c e s th a t m ade his w elcom e by the th en C h a irm a n of th e C o m m itte e (S ir Jo h n R itchie) and m em b e rs so m e w h a t frosty. D avid succeeded R itch ie as C h a irm a n in 1973 and so served u n til 1979 w hen I succeeded him .
'D av id , as a n o n -v e te rin a ria n , u n d e rto o k a very difficult task in his usual m asterly way, b rin g in g in new blood and gain in g th e B o a rd 's (and th e v e te rin a ry p ro fe ssio n 's) confidence and respect. In 1977 a h ith e rto u n k n o w n in fection a p p eared in th o ro u g h b re d m ares in the N e w m a rk et area. T h e disease, th e n n a m e d C o n tag io u s E q u in e M e tritis, caused p ro b le m s because o f th e difficulty of isolating and id en tify in g the causal o rganism . D avid b ro u g h t in suitable ex p erts from th e w ide c o m m u n ity of m icro b io lo g ists to collaborate w ith th e p a th o lo g ist at th e E q u in e R esearch S tatio n (A nim al H e a lth T r u s t) at N e w m a rk et and w ith th e staff o f th e V e te rin ary In v estig a tio n C e n tre (M .A .F .F .) at C am b rid g e. T h e in fo rm a tio n re q u ire d for tre a tm e n t and p rev e n tio n was o b tain e d in less th an th re e m o n th s. T h e " C ode of P ra c tic e " m e n tio n e d in th e a tta c h e d n o te has b een very successful it is still issued an n u ally , w ith rev isio n -th e re h av in g now b een tw o co n sec u tiv e years w ith no isolation o f th e C .E .M . o rg an ism s in th o ro u g h b re d s in th e U .K ., Ire la n d and F ra n ce , a lth o u g h it still exists in o th e r h o rs e s .' In th e fo re w o rd to th e 1977 ed itio n S ir D e sm o n d P lu m m e r, C h a irm a n of th e H o rse ra c e B e ttin g L evy B oard, states 'I w o u ld like here to pay a special trib u te to P ro fe sso r S ir D a v id E vans, F .R .S ., w ho agreed to act as C h a irm a n of th e Scientific C o m m itte e to co o rd in a te the v arious research p ro je c ts and has given u n s tin tin g ly of his tim e and e x p e rtis e .' In the 1978/79 A n n u a l R e p o rt of th e H o rse ra c e B ettin g L evy B oard it is re c o rd e d th a t 'P ro fe sso r S ir D a v id E vans re tire d as C h a irm a n of th e C o m m itte e on 30th A p ril, 1979. . . . T h e B oard w ishes to place on reco rd its a p p re c ia tio n o f th e m o st v aluable c o n trib u tio n m ade by S ir D avid, w hose c o -o rd in a tio n o f th e rese a rc h into C o n tag io u s E q u in e M e tritis ea rn e d h im in te rn a tio n a l p raise and re c o g n itio n .' P ersonal qualities D av id E vans h ad a stro n g , convivial p erso n ality . H is ru m b lin g voice and v ig o u r o f ex p ressio n ad d ed stim u lu s and c o n stru c tiv e a rg u m e n t to every g a th e rin g he a tte n d ed : his presen ce could n o t be m issed. T h e e n th u sia sm and c o m m itm e n t w ith w hich he tackled science equally e m b ra ce d his p riv ate life. H e enjoyed sw im m in g and rock clim b in g as a y o u n g m an an d , after re tire m e n t, re tu rn e d to sw im m ing, still displaying m u ch of his earlier stam ina. H is love and know ledge of the hills of N o rth W ales and th e L ake D is tric t was p ro fo u n d and in th e early 1950s, w hile at M a n ch e ster, he fre q u e n tly took his colleagues off to the Lakes to enjoy his beloved B orrow dale, Scafell and th e ir environs. W h en he m oved at last to N o rth W ales he could see th e m o u n ta in s of S now donia from the n e ig h b o u rin g hills. O ne day, a few m o n th s before he died, a couple of his old s tu d e n ts took h im up th ere and w ith th e help of a telescope he sp e n t a long tim e p o in tin g o u t the different peaks and how to clim b th em and by w h ich route: for a sh o rt tim e he was back 50 years and took his c o m p an io n s w ith him .
M usic, and especially opera, steadily becam e a m ajo r in te rest of his. A lth o u g h he enjoyed reco rd ed m usic he resp o n d e d fully only to the live p erfo rm an ces he keenly a tte n d ed in L o n d o n , at m usic festivals and w hile trav ellin g , w hen he seized every o p p o rtu n ity to visit an o p eratic p e rfo r m ance. G a rd e n in g gave him deep satisfaction, especially th e new g a rd e n he and his wife c reated w hen living at G re a t M isse n d e n . A lth o u g h D avid E vans m ig h t no t have listed conviviality as an in te re st or h o b b y , his colleagues had no d o u b t th a t social events, and especially sm all lu n ch e o n or d in n e r p a rties in a re sta u ra n t, w ere g reat sources of e n jo y m e n t to him , and to th e frie n d s fo rtu n a te e n o u g h to accom pany him on these occasions.
In his professional life he alw ays listened carefully and w ith c o n c e n tra tio n to o th ers, in c lu d in g th e m o st ju n io r of his colleagues, and so u g h t to b rin g o u t th e ir b est qu alities th ro u g h e n c o u ra g e m e n t and c o n stru c tiv e, p e n e tra tin g c o m m e n t. T h e se a ttrib u te s e x te n d e d to his social life and e n su re d th a t, w h atev er th e occasion, his co m p an y was eagerly so u g h t.
D av id enjoyed a h a p p y fam ily life. H e m a rrie d M a ry in 1937 and she survives him , w ith th e ir son and d a u g h te r and six g ra n d c h ild re n . 
